Literature DB >> 31522377

Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients.

Hye-Yoon Song1, Kyung-Bok Son1, Ju-Young Shin2, SeungJin Bae3.   

Abstract

Background Although the majority of clinical guidelines indicate the use of NOAC (nonvitamin K antagonist oral anticoagulant) over vitamin K antagonist in nonvalvular atrial fibrillation patients, there is no information on real-world prescription factors that lead to a specific type of oral anticoagulant selection. Objective To evaluate the prescription factors for choosing a specific oral anticoagulant for nonvalvular atrial fibrillation patients in Korea. Setting Nationwide sampled database in South Korea. Methods In this study, we defined nonvalvular atrial fibrillation patients as having one or more hospitalizations or two or more out-patient visits with a stroke risk score (CHA2DS2-VASc scores) ≥ 2 eligible for oral anticoagulant therapy from Jan 1st, 2016 to Dec 31st, 2016. Baseline characteristics were analyzed, including sex, age, comorbidities, CHA2DS2-VASc, bleeding risk score (mHAS-BLED), prescribing specialty, insurance type, medical institution type and location. Univariate and multivariate logistic regression analyses were conducted for being prescribed NOAC compared with vitamin K antagonist. Main outcome measure Adjusted odds ratio of the NOAC group and vitamin K antagonist group. Results Of 9,226 patients eligible for oral anticoagulant therapy, 4999 patients (54.2%) received oral anticoagulant therapy, and 4517 patients took NOAC or vitamin K antagonist only during the study period. Prior stroke, transient ischemic attack, thromboembolism, thyroid disease, dyslipidemia, cancer, mHAS-BLED ≥ 5, in-patient care, and specialty in internal medicine and neurology were positive predictors of NOAC use over vitamin K antagonist, whereas young age (≤64), renal dysfunction, and secondary care institution were negative predictors of NOAC use over vitamin K antagonist. Conclusions The presence of comorbidities was linked to NOAC use over vitamin K antagonist, which is different from prescription factor studies in other countries and requires further study.

Entities:  

Keywords:  Anticoagulant; NOAC; Nonvalvular atrial fibrillation; Prescribing; South korea; Vitamin-K antagonist

Mesh:

Substances:

Year:  2019        PMID: 31522377     DOI: 10.1007/s11096-019-00901-8

Source DB:  PubMed          Journal:  Int J Clin Pharm


  2 in total

1.  Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence.

Authors:  Eyob Alemayehu Gebreyohannes; Sandra Salter; Leanne Chalmers; Luke Bereznicki; Kenneth Lee
Journal:  Am J Cardiovasc Drugs       Date:  2020-12-28       Impact factor: 3.571

Review 2.  Women in Cardiology: Role of Social Media in Advocacy.

Authors:  Hena Patel; Annabelle S Volgman
Journal:  Curr Cardiol Rev       Date:  2021
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.